Research ExplorerPublicationsLoss of CADM1 expression is associated with poor prognosis a...

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients

Standard

Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. / Wikman-Kocher, Harriet; Westphal, Laura; Schmid, Felicitas; Pollari, Sirkku; Kropidlowski, Jolanthe; Sielaff-Frimpong, Bettina; Glatzel, Markus; Matschke, Jakob; Westphal, Manfred; Iljin, Kristiina; Huhtala, Heini; Terracciano, Luigi; Kallioniemi, Anne; Sauter, Guido; Müller, Volkmar; Witzel, Isabell; Lamszus, Katrin; Kemming, Dirk; Pantel, Klaus.

In: ONCOTARGET, Vol. 5, No. 10, 16.03.2014, p. 3076-3087.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wikman-Kocher, H, Westphal, L, Schmid, F, Pollari, S, Kropidlowski, J, Sielaff-Frimpong, B, Glatzel, M, Matschke, J, Westphal, M, Iljin, K, Huhtala, H, Terracciano, L, Kallioniemi, A, Sauter, G, Müller, V, Witzel, I, Lamszus, K, Kemming, D & Pantel, K 2014, 'Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients', ONCOTARGET, vol. 5, no. 10, pp. 3076-3087.

APA

Wikman-Kocher, H., Westphal, L., Schmid, F., Pollari, S., Kropidlowski, J., Sielaff-Frimpong, B., Glatzel, M., Matschke, J., Westphal, M., Iljin, K., Huhtala, H., Terracciano, L., Kallioniemi, A., Sauter, G., Müller, V., Witzel, I., Lamszus, K., Kemming, D., & Pantel, K. (2014). Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. ONCOTARGET, 5(10), 3076-3087.

Vancouver

Wikman-Kocher H, Westphal L, Schmid F, Pollari S, Kropidlowski J, Sielaff-Frimpong B et al. Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. ONCOTARGET. 2014 Mar 16;5(10):3076-3087.

Bibtex

@article{cb13feba5ea6486d940b26fa1dd5fe6e,
title = "Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients",
abstract = "Breast cancer brain metastases (BCBM) are detected with increasing incidence. In order to detect potential genes involved in BCBM, we first screened for genes down-regulated by methylation in cell lines with site-specific metastatic ability. The expression of five genes, CADM1, SPARC, RECK, TNFAIP3 and CXCL14, which were also found down-regulated in gene expression profiling analyses of BCBM tissue samples, was verified by qRT-PCR in a larger patient cohort. CADM1 was chosen for further down-stream analyses. A higher incidence of CADM1 methylation, correlating with lower expression levels, was found in BCBM as compared to primary BC. Loss of CADM1 protein expression was detected most commonly among BCBM samples as well as among primary tumors with subsequent brain relapse. The prognostic role of CADM1 expression was finally verified in four large independent breast cancer cohorts (n=2136). Loss of CADM1 protein expression was associated with disease stage, lymph node status, and tumor size in primary BC. Furthermore, all analyses revealed a significant association between loss of CADM1 and shorter survival. In multivariate analyses, survival was significantly shorter among patients with CADM1-negative tumors. Loss of CADM1 expression is an independent prognostic factor especially associated with the development of brain metastases in breast cancer patients.",
author = "Harriet Wikman-Kocher and Laura Westphal and Felicitas Schmid and Sirkku Pollari and Jolanthe Kropidlowski and Bettina Sielaff-Frimpong and Markus Glatzel and Jakob Matschke and Manfred Westphal and Kristiina Iljin and Heini Huhtala and Luigi Terracciano and Anne Kallioniemi and Guido Sauter and Volkmar M{\"u}ller and Isabell Witzel and Katrin Lamszus and Dirk Kemming and Klaus Pantel",
year = "2014",
month = mar,
day = "16",
language = "English",
volume = "5",
pages = "3076--3087",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "10",

}

RIS

TY - JOUR

T1 - Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients

AU - Wikman-Kocher, Harriet

AU - Westphal, Laura

AU - Schmid, Felicitas

AU - Pollari, Sirkku

AU - Kropidlowski, Jolanthe

AU - Sielaff-Frimpong, Bettina

AU - Glatzel, Markus

AU - Matschke, Jakob

AU - Westphal, Manfred

AU - Iljin, Kristiina

AU - Huhtala, Heini

AU - Terracciano, Luigi

AU - Kallioniemi, Anne

AU - Sauter, Guido

AU - Müller, Volkmar

AU - Witzel, Isabell

AU - Lamszus, Katrin

AU - Kemming, Dirk

AU - Pantel, Klaus

PY - 2014/3/16

Y1 - 2014/3/16

N2 - Breast cancer brain metastases (BCBM) are detected with increasing incidence. In order to detect potential genes involved in BCBM, we first screened for genes down-regulated by methylation in cell lines with site-specific metastatic ability. The expression of five genes, CADM1, SPARC, RECK, TNFAIP3 and CXCL14, which were also found down-regulated in gene expression profiling analyses of BCBM tissue samples, was verified by qRT-PCR in a larger patient cohort. CADM1 was chosen for further down-stream analyses. A higher incidence of CADM1 methylation, correlating with lower expression levels, was found in BCBM as compared to primary BC. Loss of CADM1 protein expression was detected most commonly among BCBM samples as well as among primary tumors with subsequent brain relapse. The prognostic role of CADM1 expression was finally verified in four large independent breast cancer cohorts (n=2136). Loss of CADM1 protein expression was associated with disease stage, lymph node status, and tumor size in primary BC. Furthermore, all analyses revealed a significant association between loss of CADM1 and shorter survival. In multivariate analyses, survival was significantly shorter among patients with CADM1-negative tumors. Loss of CADM1 expression is an independent prognostic factor especially associated with the development of brain metastases in breast cancer patients.

AB - Breast cancer brain metastases (BCBM) are detected with increasing incidence. In order to detect potential genes involved in BCBM, we first screened for genes down-regulated by methylation in cell lines with site-specific metastatic ability. The expression of five genes, CADM1, SPARC, RECK, TNFAIP3 and CXCL14, which were also found down-regulated in gene expression profiling analyses of BCBM tissue samples, was verified by qRT-PCR in a larger patient cohort. CADM1 was chosen for further down-stream analyses. A higher incidence of CADM1 methylation, correlating with lower expression levels, was found in BCBM as compared to primary BC. Loss of CADM1 protein expression was detected most commonly among BCBM samples as well as among primary tumors with subsequent brain relapse. The prognostic role of CADM1 expression was finally verified in four large independent breast cancer cohorts (n=2136). Loss of CADM1 protein expression was associated with disease stage, lymph node status, and tumor size in primary BC. Furthermore, all analyses revealed a significant association between loss of CADM1 and shorter survival. In multivariate analyses, survival was significantly shorter among patients with CADM1-negative tumors. Loss of CADM1 expression is an independent prognostic factor especially associated with the development of brain metastases in breast cancer patients.

M3 - SCORING: Journal article

C2 - 24833255

VL - 5

SP - 3076

EP - 3087

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 10

ER -